Kadimastem - Stem Cell to Cure Diseases

News & Events > Press Releases

Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M

Nov. 14, 2018

Ness Ziona, Israel, November 11, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces that, at the end of the exercise period of the company's Series 4 warrants, 4.82 warrants were exercised, constituting 97% of the total amount of the warrants.

The total gross proceeds received by the Company from the exercise of the warrants is NIS 3.6 million.

Mr. Yossi Ben-Yosef, CEO of the company, said: "I see the 97% exercise rate of the warrants as a success, and thank the warrant-holder public for its vote of confidence in the company and in its potential."


About Kadimastem

Kadimastem Ltd. (www.Kadimastem.com) is a clinical stage biotechnology company developing industrial regenerative therapies based on human embryonic stem cells (hESC) for the treatment of neurodegenerative diseases such as ALS, as well as diabetes. The company was founded in 2009 by Prof. Michel Revel and Yossi Ben Yosef and is listed on the Tel Aviv Stock Exchange (TASE: KDST). The company's chairman is Dr. Eli Opper, formerly the Chief Scientist of Israel’s Ministry of Industry, Trade, and Labor, and the company's Scientific Advisory Board consists of leading scientists and pioneers in their fields. The company's investors, in addition to its founders, include Altshuler Shaham Investment House, foreign investors (Julien Ruggieri and Avi Meizler) and additional institutional investors.

Kadimastem was founded on the basis of patent-protected technologies developed in Prof. Michel Revel’s laboratory at the Weizmann Institute of Science. Based on the company's unique technological platform, Kadimastem develops regenerative therapies to repair and replace tissues and organs by using functioning cells differentiated from stem cells. The company focuses on transplanting healthy brain cells to support the survivability of damaged nerve cells as cell therapy for ALS and transplanting insulin-producing pancreatic cell for the treatment of insulin-dependent diabetes.

Kadimastem has an extensive scientific advisory board, featuring prominent scientists and pioneers: In the embryonic stem cell field - Professor Joseph Itskovitz-Eldor, a world renowned expert and pioneer in pluripotent stem cell research and former head of Obstetrics and Gynecology at Rambam Medical Center, serves both as a director and a senior strategic consultant in the company, and Prof. Benjamin Reubinoff, Director of the Hadassah Human Embryonic Stem Cell Research Center and Senior Physician at the Department of Obstetrics and Gynecology at the Hadassah University Medical Center; in the neurodegenerative disease field - Prof. Tamir Ben Hur, Head of the Department of Neurology and Division of Medical Neurosciences at Hadassah Medical Center in Jerusalem; and in the diabetes field, Prof. Shimon Efrat, professor of Human Molecular Genetics and Juvenile Diabetes at Tel Aviv University and a world renowned expert in cell replacement therapy for diabetes, and Prof. Eddy Karnieli, former Director of the Institute for Endocrinology, Diabetes and Metabolism at the Rambam Medical Center and a world renowned expert in these fields.

Press Releases Archive